Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Current Leases (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Current Leases for 4 consecutive years, with $648000.0 as the latest value for Q4 2025.

  • Quarterly Current Leases rose 29.34% to $648000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $648000.0 through Dec 2025, up 29.34% year-over-year, with the annual reading at $648000.0 for FY2025, 29.34% up from the prior year.
  • Current Leases for Q4 2025 was $648000.0 at Phathom Pharmaceuticals, up from $591000.0 in the prior quarter.
  • The five-year high for Current Leases was $730000.0 in Q1 2024, with the low at $238000.0 in Q2 2025.
  • Average Current Leases over 4 years is $613187.5, with a median of $682500.0 recorded in 2022.
  • The sharpest move saw Current Leases surged 45.31% in 2023, then plummeted 66.94% in 2025.
  • Over 4 years, Current Leases stood at $708000.0 in 2022, then grew by 2.54% to $726000.0 in 2023, then plummeted by 30.99% to $501000.0 in 2024, then rose by 29.34% to $648000.0 in 2025.
  • According to Business Quant data, Current Leases over the past three periods came in at $648000.0, $591000.0, and $238000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.